UEGW 2025 Highlights Podcast

In this episode [14.18], Medicom’s correspondent covers 6 presentations from the United European Gastroenterology (UEG) Week, held in Berlin, Germany, and online, from 4-7 October 2025. 

The topics discussed are:  

1. High-dose obefazimod is efficacious in UC regardless of prior therapy exposure  

[00.33] Treatment with obefazimod resulted in significant and clinically meaningful improvements in patients with moderate-to-severe ulcerative colitis (UC), regardless of prior exposure to advanced therapies, according to data from the phase 3 ABTECT-1 and -2 induction trials. 

2. Endoscopic approach preferred over surgery in gastric outlet syndrome  

[02.53] In patients with gastric outlet syndrome, endoscopic gastroenterostomy resulted in a reduced time to oral intake of solid food compared with surgical gastrojejunostomy. Additionally, re-intervention rates were comparable between the two study arms. 

3. GLISTEN: Linerixibat meets primary endpoint in PBC-associated cholestatic pruritus  

[05.02] Linerixibat demonstrated rapid and clinically meaningful improvements in itch among patients with primary biliary cholangitis and cholestatic pruritus. The agent was generally well tolerated, supporting its potential as the first globally approved therapy for pruritus in PBC.  

4. Sugar-sweetened and non-sugar-sweetened beverages linked to MASLD risk  

[06.46] Both sugar-sweetened and low/non-sugar-sweetened beverages (SSBs and LNSSBs) were associated with an increased risk of metabolic dysfunction-associated steatotic liver disease (MASLD), stressing the importance of making healthy beverage choices. 

5. Relapse rate and risk factors after anti-TNF withdrawal in UC 

[09.34] Cessation of anti-tumour necrosis factor (TNF) treatment in patients with ulcerative colitis (UC) in sustained corticosteroid-free clinical remission is associated with a considerable risk of relapse after 1 year, which continues to increase over time. Younger age, anti-TNF monotherapy at the time of discontinuation, and immunomodulator-refractory disease were identified as risk factors for relapse. 

6. Can vedolizumab simplify the management of checkpoint inhibitor-induced enterocolitis? 

[11.56] Up-front vedolizumab therapy may offer a promising strategy to reduce corticosteroid use and facilitate the resumption of checkpoint inhibitors in patients with checkpoint inhibitor-induced enterocolitis. 

Enjoy listening! 

Copyright ©2025 Medicom Publishing Group 

Posted on 3 November 20253 November 2025